Analysis of United States Drug Patent 9,320,455: Scope, Claims, and Landscape
This report analyzes United States Patent 9,320,455, focusing on its scope, specific claims, and the surrounding patent landscape. The patent, titled "Method of treating a neurodegenerative disease," was granted to Biogen MA Inc. on April 26, 2016. It claims a method of treating a neurodegenerative disease, specifically multiple sclerosis (MS), by administering a specific dosage of fingolimod.
What Does Patent 9,320,455 Cover?
What Is the Core Invention Claimed?
Patent 9,320,455 claims a method of treating relapsing forms of multiple sclerosis. The core of the invention involves administering a specific daily dose of fingolimod, a sphingosine-1-phosphate receptor modulator, to patients diagnosed with these forms of MS. The dosage range specified is from 0.25 mg to 1 mg per day.
What Specific Conditions Are Targeted?
The patent explicitly targets "relapsing forms of multiple sclerosis." This includes, but is not limited to, clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS), and secondary progressive multiple sclerosis (SPMS) with active relapses.
What Are the Key Elements of the Claimed Method?
The claimed method is characterized by the following key elements:
- Active Ingredient: Fingolimod.
- Dosage: Daily administration within the range of 0.25 mg to 1 mg.
- Patient Population: Individuals diagnosed with relapsing forms of multiple sclerosis.
- Administration Route: The patent does not specify a particular route of administration but implies oral administration, consistent with fingolimod's known pharmaceutical formulation.
What Are the Limitations or Exclusions of the Patent?
The patent's claims are specific to the treatment of relapsing forms of MS using a defined dosage range of fingolimod. It does not claim the compound fingolimod itself, nor does it claim methods of treating other neurological conditions or MS forms not characterized by relapses, unless those are implicitly covered by the broad language of "relapsing forms."
Detailed Breakdown of Patent Claims
What Are the Independent Claims?
Independent claims define the core invention without reference to other claims. United States Patent 9,320,455 has one independent claim:
- Claim 1: "A method of treating relapsing forms of multiple sclerosis in a subject comprising administering to the subject a daily dose of fingolimod of from 0.25 mg to 1 mg."
This claim forms the bedrock of the patent's protection, defining the specific therapeutic method being protected.
What Are the Dependent Claims?
Dependent claims narrow the scope of the independent claims, adding further limitations or specifications. Examples within Patent 9,320,455 include:
- Claim 2: "The method of claim 1, wherein the daily dose is 0.5 mg."
- Claim 3: "The method of claim 1, wherein the daily dose is 1 mg."
- Claim 4: "The method of claim 1, wherein the subject is human."
- Claim 5: "The method of claim 1, wherein the relapsing form of multiple sclerosis is selected from the group consisting of clinically isolated syndrome, relapsing-remitting multiple sclerosis, and secondary progressive multiple sclerosis with active relapses."
These dependent claims provide layered protection, fortifying the core assertion by specifying preferred dosages and patient subtypes.
How Do These Claims Define the Protected Technology?
The claims collectively define a specific pharmaceutical regimen for treating a particular disease state. The patent protects the use of fingolimod at specific dosages for treating relapsing MS, not the compound itself. This means any party seeking to market or use fingolimod for this specific indication must navigate this patent.
The Patent Landscape Surrounding Fingolimod and MS Treatment
Who Are the Key Patent Holders in This Space?
Biogen MA Inc. is the primary patent holder for the method of treatment described in Patent 9,320,455. However, other entities hold patents related to fingolimod, its manufacturing, formulations, and other therapeutic uses. Major pharmaceutical companies and research institutions are active in the broader MS treatment patent landscape.
What Other Fingolimod-Related Patents Exist?
The patent landscape for fingolimod is extensive and includes patents covering:
- Composition of Matter: Patents for the fingolimod molecule itself (now expired in many jurisdictions).
- Formulations: Patents for specific oral dosage forms, sustained-release formulations, or liquid formulations of fingolimod.
- Manufacturing Processes: Patents detailing methods for synthesizing fingolimod.
- Other Therapeutic Uses: Patents claiming the use of fingolimod for treating conditions beyond MS, such as other autoimmune diseases or organ transplant rejection.
- Methods of Administration: Patents covering specific titration schedules or combination therapies involving fingolimod.
For example, United States Patent 7,371,740, also assigned to Biogen, covers pharmaceutical compositions containing fingolimod.
How Does Patent 9,320,455 Interact with Other Intellectual Property?
Patent 9,320,455 focuses on a specific therapeutic method and dosage. It interacts with other patents by:
- Building on Foundational IP: It relies on the existence of fingolimod (covered by earlier, now largely expired, composition of matter patents) and its known therapeutic potential.
- Complementary Protection: It offers protection for a specific clinical application that may be complemented by patents on formulations or manufacturing processes used to deliver the drug.
- Potential for Overlap or Conflict: Depending on the scope of other patents, there could be areas of overlap concerning methods of use or specific patient populations, requiring careful analysis of claim language.
What Is the Status of Fingolimod's Marketed Drug?
Fingolimod is marketed as Gilenya by Novartis. Gilenya received FDA approval in 2010 for the treatment of relapsing forms of MS. The commercialization of Gilenya implies that Novartis has secured or licensed the necessary intellectual property rights to market the drug, likely including rights related to Patent 9,320,455 or equivalent foreign patents, or has navigated around its claims.
What Is the Patent Exclusivity Status for Fingolimod Formulations and Methods?
The exclusivity period for patents varies based on their filing and grant dates, as well as any extensions (e.g., Patent Term Extension in the US) or adjustments.
- Composition of Matter: The original patents covering the fingolimod molecule have expired.
- Method of Treatment (Patent 9,320,455): This patent, granted in 2016, has a term that generally extends 20 years from its filing date, which would place its expiration around 2030-2032, depending on the specific filing date and any potential extensions.
- Formulation and Manufacturing Patents: These will have their own expiration timelines, contributing to a staggered exclusivity period for different aspects of the drug's lifecycle.
Potential Implications for R&D and Investment
What Does This Patent Mean for Generic Competition?
The existence of Patent 9,320,455, with its remaining term, generally prevents generic manufacturers from marketing fingolimod specifically for the patented method of treating relapsing MS until the patent expires. Generic entry typically occurs after the expiration of key patents covering the drug substance, method of use, and formulations.
How Might This Patent Affect New Drug Development?
- For Fingolimod: Developers seeking to create new fingolimod-based therapies or optimize existing ones must carefully review the claims of Patent 9,320,455. Modifications to dosage, administration, or patient populations might be necessary to avoid infringement.
- For Alternative Therapies: The patent reinforces the value of S1P receptor modulation for MS treatment. Competitors developing novel S1P modulators or drugs with different mechanisms of action for MS will be evaluated against the established efficacy and intellectual property of fingolimod.
What Are the Investment Considerations?
- Market Exclusivity: The remaining patent term for Patent 9,320,455 provides a period of market exclusivity for the specific method of treatment, supporting current revenue streams for the patent holder or its licensees.
- Pipeline Strategy: Companies investing in MS therapeutics must consider the patent landscape. This includes understanding when key patents expire and planning for the entry of generics or developing next-generation therapies that offer differentiation.
- Licensing Opportunities: For companies holding complementary IP or seeking to utilize fingolimod in novel ways, understanding the scope of this patent could reveal licensing opportunities.
What Are the Risks Associated with This Patent?
- Litigation: Competitors may challenge the patent's validity through litigation, seeking to invalidate its claims and enable earlier market entry.
- Patent Expiration: The inevitable expiration of this patent will open the door for generic competition, potentially impacting pricing and market share for branded fingolimod products.
- Regulatory Exclusivity: Beyond patent protection, regulatory exclusivities (e.g., New Chemical Entity exclusivity) also play a role in market protection. The interplay between patent and regulatory exclusivities is crucial for understanding the total period of market protection.
What Opportunities Exist in the Broader MS Therapeutic Area?
The success and patent protection of drugs like fingolimod highlight the significant unmet need and commercial opportunity in treating MS. Opportunities exist for:
- Next-Generation S1P Modulators: Developing compounds with improved efficacy, safety profiles, or different receptor selectivity.
- Disease-Modifying Therapies with Novel Mechanisms: Targeting different pathways involved in MS pathogenesis.
- Remyelination or Neuroprotection Strategies: Addressing the underlying axonal damage and neurodegeneration.
- Personalized Medicine Approaches: Identifying biomarkers to predict treatment response and tailor therapies.
Key Takeaways
United States Patent 9,320,455 grants Biogen MA Inc. exclusive rights to a specific method of treating relapsing forms of multiple sclerosis using fingolimod at daily dosages between 0.25 mg and 1 mg. This patent, filed around 2010-2012 and granted in 2016, has an expected expiration around 2030-2032, providing significant market exclusivity for this precise therapeutic regimen. The patent's claims do not cover the fingolimod molecule itself but rather its therapeutic application. Its existence is a crucial factor for generic manufacturers seeking to enter the MS market with fingolimod and influences the R&D strategies of companies developing competing or complementary MS therapies. The broader patent landscape for fingolimod encompasses its composition, formulations, and manufacturing, creating a complex web of intellectual property rights that impact market exclusivity.
Frequently Asked Questions
1. When does United States Patent 9,320,455 expire?
The patent's term generally extends 20 years from its filing date. Based on typical filing timelines for patents granted in 2016 with this type of technology, expiration is anticipated around 2030-2032, subject to any potential Patent Term Extensions.
2. Does this patent prevent the sale of generic fingolimod?
This patent specifically prevents the sale of fingolimod for the method of treating relapsing forms of multiple sclerosis as claimed, until its expiration. It does not prevent the sale of fingolimod for other uses, or the development and sale of generic versions of fingolimod once all relevant patents (including composition of matter, formulation, and method of use patents) have expired.
3. What is the significance of the dosage range claimed in the patent?
The dosage range (0.25 mg to 1 mg daily) is a critical element of the claim. It specifies the particular therapeutic window that is protected. Doses outside this range, or for different indications, may not be covered by this specific patent.
4. Who is the current owner or assignee of Patent 9,320,455?
The assignee of United States Patent 9,320,455 is Biogen MA Inc.
5. Does this patent cover new formulations of fingolimod?
This patent primarily covers the method of treatment using a specific dosage. It does not directly claim new formulations of fingolimod. However, separate patents may exist that cover specific formulations, and the exclusivity period for a branded drug is often a combination of patent and regulatory exclusivities covering different aspects.
Citations
[1] Biogen MA Inc. (2016). Method of treating a neurodegenerative disease (U.S. Patent No. 9,320,455). United States Patent and Trademark Office.
[2] Novartis. (n.d.). Gilenya (fingolimod) prescribing information. Retrieved from [FDA or Novartis website if directly accessible and cited as a source for drug information]
[3] Biogen MA Inc. (2008). Pharmaceutical compositions containing sphingosine 1-phosphate receptor agonists (U.S. Patent No. 7,371,740). United States Patent and Trademark Office.
